ADVISORY, Oct. 06, 2017 (GLOBE NEWSWIRE) --
Verona Pharma plc (Nasdaq:VRNA), a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases with high unmet medical need, will visit the Nasdaq MarketSite in Times Square.
In May, the Company completed financing of $90 million through a global offering comprising an IPO on the NASDAQ Global Market and a concurrent European private placement, together with a shareholder private placement. Verona Pharma was also recently awarded the 2017 Biotech and Money UK Life Science IPO of the Year Award, and named as finalist for Scrip’s 2017 Financing of the Year Award.
In honor of the occasion, Jan-Anders Karlsson, Chief Executive Officer and Executive Director, along with a group of Verona Pharma colleagues, will ring the Closing Bell.
Verona Pharma’s lead product candidate, RPL554, is a first-in-class inhaled compound with both bronchodilator and anti-inflammatory effects and is being investigated for the treatment of chronic obstructive pulmonary disease and cystic fibrosis, two debilitating respiratory diseases with significant gaps in current treatment options for patients.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Monday, October 9, 2017 – 3:45 p.m. to 4:00 p.m. ET
US Media and Investor Inquiries:
James Heins (media) / Stephanie Carrington (investors)
203-682-8251 / 646-277-1282
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.